Dolutegravir and lamivudine have been approved by the US
FDA as the first fixed-dose, complete regimen for the treatment of human
immunodeficiency virus type 1 (HIV-1) infection in adults with no
antiretroviral treatment history and with no known or suspected substitutions
associated with resistance to the individual components of the drug.
Currently, the standard of care for patients who have
never been treated is a 3-drug regimen.
With this approval, patients who have never been treated
have the option of taking a two-drug regimen in a single tablet while
eliminating additional toxicity and potential drug interactions from a third
drug.
Patients infected with both HIV and hepatitis B should
add additional treatment for their hepatitis B or consider a different drug
regimen.
Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of
Medical Associations in Asia and Oceania
(CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of
India
Past National President
IMA
No comments:
Post a Comment